Dr Axel Merseburger is the chairman of the Department of Urology at the University Hospital Schleswig-Holstein in Lübeck, Germany.
His key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors.
He is a member of the European Association of Urology (EAU) Guideline Groups on Renal Cell Cancer and has served as national and international principal investigator in several phase II/III clinical trials.
His molecular and clinical research has won multiple awards, stipends and prizes, and he has authored and co-authored more that 200 publications.